Exom Group starts Caravaggio Study, Cloud & Mobile Clinical Trial
Amsterdam–June 7, 2017-At the European Investigators’ meeting in Amsterdam, Netherlands, Exom Group “The Human Digital CRO,” headquartered in Milano, Italy-launched the Caravaggio Study, an industry Cloud & Mobile Clinical Trial, that will randomize about 1,200 patients from 160 clinical sites across Europe, Israel, and the U.S.
The study is assessing the efficacy and safety of a DOAC in the treatment of VTE complications in cancer patients.
The real innovation of this study is the full digital conduction and oversight through Genius SUITE®, an integrated multi-modular cloud platform that enables real-time and on-line management of the multi-functions spectrum of clinical trial operations.
Genius SUITE® combines in one study portal many functionalities from the electronic Informed Consent (eIC), Randomization and Drug Supply, to the eTMF, RBM, and eSource:
With Genius SUITE®, both studys’ sponsors and investigators can accelerate trial execution and gain real-time visibility into any trial related operations.
“The conduction and oversight of a clinical trial is an highly complex and often inefficient ecosystem due to a number of factors, including the inconsistent use of a large number of disparate and incompatible technologies,” said Luigi Visani, President & CEO of Exom Group ,
“Real-time and mobile access, compatibility, integration and completeness are critical factors driving technology solutions adoption among clinical research professionals and patients. Exom Group is bringing the next generation of clinical trial to the clinical research stakeholders. We are revolutionizing the CRO industry with the unique combination of human professional skills and services with a unified suite of applications to provide one process, one system, and one view within and across clinical trials , while reducing costs and increasing quality and performance “.
Additional Information
For more on Exom Group and/or Genius SUITE® : info@exomgroup.com
About Exom Group srl
Exom Group is “The Human Digital CRO” , that provides cloud technological solutions & value-added services for clinical development of drugs & medical devices. We combine the strong medical, regulatory and operational expertise of our staff , with the most disruptive digital cloud technological solutions to reduce costs and increase quality and performance of Clinical Trials. Exom Group is headquartered in Milano (Italy) and operates in all Europe and USA.
For more information visit www.exomgroup.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
